We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Charles River Laboratories Signs Licensing Agreement with Luminex
News

Charles River Laboratories Signs Licensing Agreement with Luminex

Charles River Laboratories Signs Licensing Agreement with Luminex
News

Charles River Laboratories Signs Licensing Agreement with Luminex

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Charles River Laboratories Signs Licensing Agreement with Luminex"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Charles River Laboratories International, Inc. and Luminex Corporation have announced that they have entered into a licensing agreement whereby Charles River will utilize Luminex's xMAP® technology within Charles River's Research Models and Services business segment.

The Luminex xMAP technology is designed to enable multiple assays to be performed in a single well, or multiplexed, utilizing suspended microspheres or beads. Up to 100 different simultaneous assays can be performed in a single microtiter well.

Charles River's Research Animal Diagnostic Services division will use the technology to create the Multiplexed Fluorometric ImmunoAssay (MFIA), which will be adopted as the platform for screening laboratory animal serum samples for infectious disease.

William Barbo, Charles River Laboratories Corporate Vice President, Research Model Services, said, "Charles River is pleased to join Luminex in this licensing agreement."

"The use of Luminex's xMAP technology in the form of MFIA will allow us the flexibility to further refine and expand our assays, delivering unparalleled products and services in the area of laboratory animal diagnostics."

Russell Bradley, Vice President of Business Development and Strategic Planning, Luminex Corporation, said, "We are pleased Charles River Laboratories has selected our xMAP technology as their multiplex platform of choice for the standardization of animal diagnostic assays."

"As a market leader, Charles River Laboratories joins a growing team of Luminex partners bringing the benefits of Luminex's bead based multiplexing to their customers."

Advertisement